Get notified when PFE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Net Loss of $248.0 Million (worsened) — Pfizer swung from a $3.0 billion pre-tax income in Q2 2025 to a $653 million pre-tax loss in Q2 2026, driven by impairments, legal charges, and higher costs.
- Revenue Growth Slowed to 2.6% (worsened) — Operational revenue growth was only 1%, down from 10% in Q2 2025, reflecting declines in COVID-19 product revenues and other products.
- Patent Expiries Expected to Reduce Revenue By $1.1 Billion In 2026 (new) — Pfizer quantified the expected 2026 revenue impact from patent-based or regulatory exclusivity expiries at $1.1 billion, a significant headwind.
- Voluntary Withdrawal of Oxbryta (new) — Pfizer notified the FDA that it is voluntarily withdrawing the NDAs for Oxbryta, a sickle cell disease drug, which could affect future revenue.
revenue $15.0B, net income -$248.0M. Pfizer swings to a loss as impairments and legal charges hit, while revenue edges up 2.6%
Filed August 4, 2026 · Period ending June 28, 2026 · Compared to 10-Q Aug 5, 2025 · ~2 min read
Key Changes
-
high
Pfizer reported a net loss of $248.0 million, or -$0.04 per share, in Q2 2026, swinging from a $3.0 billion pre-tax income a year ago, driven by intangible asset impairments, legal charges, and higher costs.
MD&A: Income from continuing operations verify on EDGAR → -
high
Total revenue rose 2.6% to $15.0 billion, but operational growth was only 1%, with foreign exchange adding 1%; growth slowed sharply from 10% in Q2 2025.
MD&A: Revenue performance verify on EDGAR → -
high
Pfizer announced new cost-cutting phases: $1.0 billion in additional net savings from the Realigning Our Cost Base Program and $1.5 billion from Manufacturing Optimization, with combined one-time costs of $6.0 billion through 2029.
MD&A: Restructuring programs verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SAIC 10-Q) is open in full — no account needed.
Partner
Trade PFE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify